Expression and mechanism of plasma miR-372 in acute myeloid leukemia patients
10.3969/j.issn.1006-5725.2018.12.027
- VernacularTitle:急性髓系白血病患者miR-372的表达水平及其临床意义
- Author:
Qiangqiang ZHAO
1
;
Jianming FENG
;
Wenqian LI
;
Kuo SHEN
;
Shaobin CHEN
;
Youbang XIE
;
Changming ZHAO
;
Yan HOU
Author Information
1. 青海省人民医院血液科
- Keywords:
MiR-372;
plasma;
acute myeloid leukemia;
PTEN
- From:
The Journal of Practical Medicine
2018;34(12):2030-2034
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of miR-372 in the plasma of patients with acute my-eloid leukemia(AML)and the possible mechanism to participate in the development of AML. Methods Real-time quantitative PCR was used to detect the level of miR-372 in plasma. Bioinformatics software predicted the pos-sible target genes of miR-372 and dual luciferase reporter assay was performed to validate the prediction. In HL-60 cells,miR-372 was knocked down,and the effects on cell migration and cloning were detected by scratch test and clone formation. Results The level of miR-372 was significantly up-regulated in the plasma of AML patients. ROC analysis showed that miR-372 could distinguish between AML patients and healthy controls. Dual luciferase report-er assay showed that miR-372 could inhibit the activity of PTEN-3'UTR. Inhibition of miR-372 in HL-60 cells can significantly reduce the cell migration rate and clone formation ability. Conclusion In summary,for the first time,we showed novel data that the level of miR-372 was increased in the plasma of AML patients. By targeting the tumor suppressor gene PTEN,miR-372 may become a potential noninvasive biomarker for the screening and di-agnosis of AML.
